Rather surprisingly, US biotech firm Nektar Therapeutics (Nasdaq: NKTR) was trading down 4.32% at $72.39 pre-market this morning, even though news had broken that it has entered into a collaboration which, including an equity investment, could be worth a record-breaking $3.6 billion. However, after the market opened, the stock started moving up around 8% to $81.74 by mid-morning.
Nektar has executed a global strategic development and commercialization collaboration with pharma major Bristol-Myers Squibb (NYSE: BMY) for its lead immuno-oncology program, NKTR-214, as B-MS searches for a competitive edge over Keytruda (pembrolizumab) and other rival checkpoint inhibitors.
Under the collaboration, the companies will jointly develop and commercialize NKTR-214 in combination with B-MS’ Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) in more than 20 indications across nine tumor types, as well as potential combinations with other anti-cancer agents from either of the respective companies and/or third parties.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze